Cipla launches Covi-G — a new rapid antibody detection test for COVID-19 which will give you results in less than 10 minutes
Nov 18, 2020, 10:32 IST
- The company has signed a deal with the manufacturer of the kit – Belgium-based Multi G and will be responsible for distributing the kits.
- Cipla will distribute the kits across over 25 markets in Asia, Middle-East and North Africa, Latin America, EU, and Australia.
- The antibody test will also be able to detect whether a person had a suspected asymptomatic or mild infection in the past.
Advertisement
Pharmaceutical giant Cipla has launched a rapid antibody detection test for COVID-19, which will give results within ten minutes. The test kit will be sold under the brand name Covi-G.The company has signed a deal with the manufacturer of the kit – Belgium-based Multi G and will be responsible for distributing the kits.
Cipla will distribute the kits across over 25 markets in Asia, Middle-East and North Africa, Latin America, EU, and Australia.
“It tests for both IgM and IgG antibodies, using a single-prick blood test using the test result indicator visual interpretation,” said the company.
The antibody test will also detect whether a person had a suspected asymptomatic or mild infection in the past, which will subsequently result in a higher number of eligible plasma donors.
Advertisement
While the company is awaiting approval by ICH country regulators, Cipla said that Covi-G has already been commercialised in over 20 countries and its sensitivity and specificity exceeds 92%. This is important as in the past, the accuracy of rapid test kits for COVID-19 has often been questioned and has quite often required a second lab test for confirmation.
What is an antibody test?
An antibody test checks for the presence of antibodies in a person. When your body fights COVID-19, it builds antibodies against the virus. This test would determine whether the body has built immunity against the virus or whether a person was infected in the past.
SEE ALSO:
COVID-19 vaccine latest updates: Sinovac’s CoronaVac safe, early trial results show that vaccine triggers immune response
IndiaMart and JD Mart gear up for a legal battle over copyright infringement — even as Justdial calls IndiaMart’s allegations ‘baseless’